A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer

Cancer Chemotherapy and Pharmacology

Volumn 74, Issue 2, 2014, Pages 277-282

  Ahn, Hee Kyung ^a   Jung, Minkyu ^a,b   Sym, Sun Jin ^a   Shin, Dong Bok ^a   Kang, Shin Myung ^a   Kyung, Sun Young ^a   Park, Jeong Woong ^a   Jeong, Sung Hwan ^a   Cho, Eun Kyung ^a  

^a Gachon University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Chemotherapy; Gemcitabine; Genexol PM; Non small cell lung cancer; Paclitaxel

Indexed keywords

ANTIHISTAMINIC AGENT; GEMCITABINE; PACLITAXEL; STEROID;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; HEART LEFT VENTRICLE FAILURE; HUMAN; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MALE; MYALGIA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; THROMBOCYTOPENIA;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DEOXYCYTIDINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPOSOMES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NANOPARTICLES; NEOPLASM STAGING; PACLITAXEL; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 84907599028     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2498-5     Document Type: Article

References (16)

1. Jung KW, Won YJ, Kong HJ, Oh CM, Shin A, Lee JS (2013) Survival of Korean adult cancer patients by stage at diagnosis, 2006-2010: national cancer registry study. Cancer Res Treat 45(3):162-171. doi:10.4143/crt.2013.45.3.162
2. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346(2):92-98. doi:10.1056/NEJMoa011954 (Pubitemid 34438899)
3. Georgoulias V, Papadakis E, Alexopoulos A, Tsiafaki X, Rapti A, Veslemes M, Palamidas P, Vlachonikolis I (2001) Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 357(9267):1478-1484. doi:10.1016/S0140-6736(00)04644-4 (Pubitemid 32488857)
4. Kosmidis P, Mylonakis N, Nicolaides C, Kalophonos C, Samantas E, Boukovinas J, Fountzilas G, Skarlos D, Economopoulos T, Tsavdaridis D, Papakostas P, Bacoyiannis C, Dimopoulos M (2002) Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 20(17):3578-3585 (Pubitemid 34983216)
5. Kosmidis PA, Fountzilas G, Eleftheraki AG, Kalofonos HP, Pentheroudakis G, Skarlos D, Dimopoulos MA, Bafaloukos D, Pectasides D, Samantas E, Boukovinas J, Lambaki S, Katirtzoglou N, Bakogiannis C, Syrigos KN (2011) Paclitaxel and gemcitabine versus paclitaxel and vinorelbine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol 22(4):827-834. doi:10.1093/annonc/mdq445
6. Kosmidis PA, Kalofonos HP, Christodoulou C, Syrigos K, Makatsoris T, Skarlos D, Bakogiannis C, Nicolaides C, Bafaloukos D, Bamias A, Samantas E, Xiros N, Boukovinas I, Fountzilas G, Dimopoulos MA (2008) Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group. Ann Oncol 1(1):115-122. doi:10.1093/annonc/mdm430
7. Park SH, Hong J, Kim YS, Kim Y, Kyung SY, An CH, Lee SP, Park JW, Jeong SH, Park J, Cho EK, Shin DB, Lee JH (2008) Phase II trial of weekly docetaxel and gemcitabine for previously untreated, advanced non-small cell lung cancer. Lung Cancer 62(1):72-77. doi:10.1016/j.lungcan.2008.02.001
8. Smit EF, van Meerbeeck JP, Lianes P, Debruyne C, Legrand C, Schramel F, Smit H, Gaafar R, Biesma B, Manegold C, Neymark N, Giaccone G (2003) Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol 21(21):3909-3917. doi:10.1200/JCO.2003.03.195 (Pubitemid 46606203)
9. Gelderblom H, Verweij J, Nooter K, Sparreboom A (2001) Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 37(13):1590-1598 (Pubitemid 32778603)
10. Kim TY, Kim DW, Chung JY, Shin SG, Kim SC, Heo DS, Kim NK, Bang YJ (2004) Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 10(11):3708-3716. doi:10.1158/1078-0432.CCR-03-0655 (Pubitemid 38697604)
11. Kim DW, Kim SY, Kim HK, Kim SW, Shin SW, Kim JS, Park K, Lee MY, Heo DS (2007) Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol 18(12):2009-2014. doi:10.1093/annonc/mdm374 (Pubitemid 350286241)
12. Lim WT, Tan EH, Toh CK, Hee SW, Leong SS, Ang PC, Wong NS, Chowbay B (2010) Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol-PM) in patients with solid tumors. Ann Oncol 21(2):382-388. doi:10.1093/annonc/mdp315
13. Kim ST, Park KH, Oh SC, Seo JH, Kim JS, Kim YH, Shin SW (2012) Chemotherapy in patients older than or equal to 75 years with advanced non-small cell lung cancer. Cancer Res Treat 44(1):37-42. doi:10.4143/crt.2012.44.1.37
14. Lee KS, Chung HC, Im SA, Park YH, Kim CS, Kim SB, Rha SY, Lee MY, Ro J (2008) Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat 108(2):241-250. doi:10.1007/s10549-007-9591-y (Pubitemid 351311357)
15. Lee JL, Ahn JH, Park SH, Lim HY, Kwon JH, Ahn S, Song C, Hong JH, Kim CS, Ahn H (2012) Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum. Invest New Drugs 30(5):1984-1990. doi:10.1007/s10637-011-9757-7
16. Park JH, Lee SH, Keam B, Kim TM, Kim DW, Yang SC, Kim YW, Heo DS (2012) EGFR mutations as a predictive marker of cytotoxic chemotherapy. Lung Cancer 77(2):433-437. doi:10.1016/j.lungcan.2012.03.020